IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4497-4501

  Zhang, Xiaoying ^a   Yin, Peiji ^a   Di, Dongmei ^a   Luo, Guanghua ^a   Zheng, Lu ^a   Wei, Jiang ^a   Zhang, Jun ^a   Shi, Yuanping ^a   Zhang, Jichen ^a   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

IL 6; JAK2 STAT3; Lung cancer; MMP 10

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; STROMELYSIN 2;

ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 10; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 75149192643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
2. Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA, Mearns AJ, Bibby MC, Anthoney A and Loadman PM: MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6: 777-785, 2004.
3. Duffy MJ and McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 12: 1343-1348, 1998.
4. Puente XS, Sanchez LM, Overall CM and Lopez-Otin C: Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4: 544-558, 2003.
5. Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S and Kanetake H: Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 52: 791-797, 2007.
6. Aung PP, Oue N, Mitani Y, Mitani Y, Nakayama H, Yoshida K, Koguchi T, Bosserhoff AK and Yasui W: Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25: 2546-2557, 2006.
7. Seargent JM, Loadman PM, Martin SW, Naylor B, Bibby MC and Gill JH: Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 65: 815-820, 2005.
8. Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK and Ralhan R: Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Pre 26: 211-222, 2002.
9. Kerkela E, Ala-aho R, Lohi J, Grenman R, M. Kahari V and Saarialho-Kere U: Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer 84: 659-669, 2001.
10. Zhang X, Zhu S, Luo G, Zheng L, Wei J, Zhu J, Mu Q and Xu N: Expression of MMP-10 in lung cancer. Anticancer Res 27: 2791-2795, 2007.
11. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289: L446-453, 2005.
12. Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663, 2007.
13. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2): 297-314, 1998.
14. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbin PD, Gadiparthi S, Burke NA, Watkins SF and Grandis JR: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 100: 4138-4143, 2003.
15. Mejias-Luque R, Peiro S, Vincent A, Van Seuningen I and de Bolos C: IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 1785: 1728-1736, 2008.
16. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K and Yoshida K: Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25: 1195-1204, 2006.
17. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ and Young CY: Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res 53: 878-886, 2009.
18. Li WQ, Dehnade F and Zafarullah M: Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166: 3491-3498, 2001.
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
20. Won HH, Park I, Lee E, Kim JW and Lee D: Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach. BMC Bioinformatics 10(Suppl 1): S53, 2009.
21. Zhang X and Darnell JE Jr: Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J Biol Chem 276: 33576-33581, 2001.
22. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J and Yu H: Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25: 7432-7440, 2005.